individuals are becoming more frequently eligible for solid-organ transplantation. However, only scarce data are available on how immunosuppressive (IS) strategies relate to transplantation outcome and immune function. We determined the impact of transplantation and immune-depleting treatment on CD4+ T-cell counts, HIV-, EBV-, and Cytomegalovirus (CMV)-viral loads and virus-specific T-cell immunity in a 1-year prospective cohort of 27 HIV(+) kidney transplant recipients. While the results show an increasing breadth and magnitude of the herpesvirus-specific cytotoxic T-cell (CTL) response over-time, they also revealed a significant depletion of polyfunctional virusspecific CTL in individuals receiving thymoglobulin as a lymphocyte-depleting treatment. The disappearance of polyfunctional CTL was accompanied by virologic EBV-reactivation events, directly linking the absence of specific polyfunctional CTL to viral reactivation. The data provide first insights into the immune-reserve in HIV+ infected transplant recipients and highlight new immunological effects of thymoglobulin treatment. Long-term studies will be needed to assess the clinical risk associated with thymoglobulin treatment, in particular with regards to EBV-associated lymphoproliferative diseases.
Introduction

The availability of antiretroviral therapy (ART) has changed the long-term clinical management of HIV infection and chronic renal failure is now increasingly prevalent in the HIV(+) population. In fact, in HIV(+) individuals treated with ART, chronic kidney, liver and heart diseases have replaced opportunistic malignancies and infections as the leading cause of mortality (1-3). Chronic renal failure in HIV(+) individuals can be due to direct effects of HIV infection (HIV-associated nephropathy/HIVAN), or result from immune-complex glomerulonephritis, ART drug toxicity or co-morbid diseases such as hypertension and diabetes (4-6). Kidney transplantation is considered the most effective treatment modality for end-stage renal disease (ESRD)
and has been successfully attempted in the HIV(+) setting, notwithstanding a somewhat elevated occurrence of acute rejection episodes (7) (8) (9) (10) (11) (12) (13) (14) . Accordingly, the use of appropriate immunosuppressive (IS) 
regimens in this setting is a matter of debate more so than the generally well tolerated ART. In particular, IS regimens including thymoglobulin (ATG), have been associated with an accelerated long-term CD4+ T-cell depletion and increased risk of non-opportunistic infections and may thus hamper overall clinical outcome in this patient group (15).
Among opportunistic complications, Epstein-Barr virus (EBV)-and Cytomegalovirus (CMV)-associated diseases are among the most dreaded ones in solid-organ transplant recipients (16-21). Although effective immune control of these pathogens has been demonstrated in healthy subjects and by adoptive T-cell transfer approaches, the knowledge on HIV-, EBV-and CMV-specific immunity in the context of solid-organ transplantation is limited and the understanding of the virus-specific immunological reserve of HIV(+) kidney transplant recipients subjected to iatrogenic IS being especially poor. However, a better understanding of factors associated with loss of immune control over viral infections may be needed to ensure best possible clinical outcome of organ transplantation and to make optimal use of available organs. By longitudinally enumerating CD4+ T-cells, quantifying HIV, EBV and CMV viral loads, and assessing the breadth, magnitude and functionality of virusspecific CD8+ T-cell responses in HIV(+) kidney transplant recipients we sought to gain insight into the complex relation between iatrogenic IS, viral pathogens and host immunity.
Material and Methods
Study participants
Viral loads
Plasma CMV DNA was quantified as previously described (22) . The lower limit of detection for CMV DNA was 1000 copies/mL (23) . CMV reactivation was defined here as any single or repeated newly detectable plasma CMV viral load in latently infected individuals.
Cellular EBV viral loads were also determined using previously methods (24, 25 (26) .
ELISpot assays
ELISpot assays were carried out as previously described (27, 28 (27) . A set of 38 CMV-derived CD8+ T-cell epitopes was included to assess CMV-specific T-cell reactivity (27) . Given Figure 3 , ATG treatment appears to induce a more vigorous and (7, 8, 10, 37 
Statistical analysis
The breadth and magnitude of virus-specific CD8+T-cell responses as well as the CD4+ T-cell counts in study participants were compared between time points using non-parametric unpaired Kruskal-Wallis tests and nonparametric paired Wilcoxon Signed Rank tests, whereas the frequencies of individual CD8+ T-cell responses
, Panels E and F). ATGtreated individuals did not differ significantly from the ATG untreated group (p > 0.05).
Cellular host immune responses to CMV increase over the first year posttransplantation CMV reactivation was detected in four of the 25 transplant recipients that were CMV infected at the pretransplantation time point (Figure 2, Panel G). These included 3 of the 7 [42.8%] subjects that received ATG and for whom follow-up CMV viral loads were available and one of the nine [11.1%] transplant recipients that did not receive ATG (p = 0.26). We then assessed the CMV-specific T-cell reactivity and pretransplantation responses were detected in 23 [92.0%] of the 25 CMV-infected subjects. CMVspecific responses pre-and posttransplantation were again
Loss of Polyfunctional CD8+ T-cell Responses in HIV-infected Kidney Transplant Recipients Figure 2: Kinetics of viral loads, and breadth and magnitude of HIV-, EBV-and CMV-specific CD8+ T-cell responses in HIV(+) kidney transplant recipients. (Panel A) shows HIV viral loads before and after transplantation. HIV viral loads are expressed as copies per mL plasma/serum. Note that most measurements showed viremia below the detection limit of the assay (<50 copies/mL) and thus fall on the x-axis. (Panel B and C) show the ex vivo assessment of the breadth and magnitude of HIV-specific CD8+ T-cell responses before and after transplantation as assessed by ELISpot assays. Similarly, (Panels D-F) show longitudinal measurements of EBV viral loads (in copies/10 5 cells; median of 7 measurements per patient) and breadth and magnitude of the EBV-specific CD8+ T-cell response
Reduction in effector functions in virus-specific T-cell responses posttransplantation are driven by ATG and are associated with EBV reactivation episodes To investigate the reason(s) why ATG-treated and ATGuntreated patients show such differences in control of EBVreactivation, notwithstanding very comparable breadths and magnitudes of their EBV-specific CD8+ T-cell responses, the effector functionality of HIV-, EBV-and CMVderived peptide specific CD8+ T-cell responses were assessed longitudinally. Although a potential association between functional competence of specific CTL populations and viral control could only be expected, if at all, in the case of EBV, for which prophylactic or therapeutic effect of antiviral agents is less well established as for HIV and CMV, T-cell responses to HIV and CMV (which were under efficient pharmacological control) were analyzed as well to determine the effect of ATG on antiviral immune responses across different viruses (33).
The functional analyses were based on the ability of CD8+ T-cells to react to antigen stimulation with the secretion of the cytokines IFN-c , TNF-a and/or IL-2. First, each response was assigned one of the seven possible combinations of effector functions as listed in Figure 3 and the relative (%) contribution of each combination to the total virus-specific response across all subjects (from each group; i.e. ATG-treated an ATG-naïve transplant recipients) at any given time point was recorded. As shown in
of HIV-reactive CD8+ T-cells of ATG-treated and ATG-untreated HIV(+) kidney transplant recipients, respectively. The composition is expressed as percentage of total HIV specific CD8+ T-cells, i.e. encompassing all ATG-treated and -untreated recipients, respectively. Likewise, (Panels B and E and C and F) represent the functional composition of CMV-and EBV-responsive CD8+ T-cells in patients that did or did not receive ATG treatment, respectively. transiently complete, depletion of tri-functional antiviral CD8+ T-cell responses than ATG-free IS regimen, although this comparison did not reach statistical significance. ATG-treated individuals experienced a similar drop in tri-functional cells specific for CMV at week 12.
Since this analysis was designed to encompass all individual immune responses within each group and to provide an overall assessment of the effector function patterns, responses of smallest or greatest magnitude were attributed the same weight. We thus potentially overestimated the contribution of weak responses to the total virus-specific immunity. To compensate for this potential bias, we then compared all individual responses based on their effector function profile and their frequency in the CD8+ T-cell pool of each patient, for each virus separately and between preand posttransplantation time points (Figure 4). Responses were recorded either as mono-, bi-or tri-functional and their frequency compared between ATG-treated and ATGuntreated individuals. As shown in Figure 4, panel A, the frequencies of HIV, EBV and CMV-specific CD8+ T-cells that responded with only one detectable effector function were largely unaffected by IS regimens, as for all viruses the ATG treated and ATG untreated individuals showed comparable magnitudes of responses pre-versus posttransplantation. In contrast, we observed an almost complete absence of bi-and tri-functional responses in ATGtreated subjects compared to ATG-untreated individuals at posttransplantation time points (i.e. panels B and C: EBVspecific CD8+ T-cell immune responses [p < 0.001] as well as bi-and tri-functional HIV-specific CD8+ T-cell responses [both p < 0.05]). Importantly, ATG-treated and
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ATG-untreated individuals had comparable pretransplantation frequencies of mono-, bi-and tri-functional CD8+ Tcells specific for HIV, EBV and CMV. To test for a possible link between the relative absence of bi-and tri-functional CD8+ T-cells and viral control, the effector function profiles of CTL specific for EBV were compared to the occurrence of reactivation of EBV-replication (Figure 4 panel D). Individual EBV-specific CD8+ T-cells
